Clinical trials: Phase 1
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple…
- Trial name
- NCT02119468
- Testing
- ixazomib citrate, dexamethasone, pomalidomide
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Advanced Solid Tumors
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04362748
- Testing
- AMG 256
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Amgen
Healthy Participants
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Single-dose, double-blind, randomized, three-period, three-treatment, six-sequence, crossover study to demonstrate pharmacokinetic and pharmacodynamic similarity between NKF-INS Glargine (G), United States (US)-Lantus®, and…
- Trial name
- NCT06627478
- Testing
- NKF-INS(G), US-Lantus®, EU-Lantus®
- Where
- South Africa
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03581487
- Testing
- Durvalumab, Selumetinib, Tremelimumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
This phase I/II trial studies the side effects of avelumab when given in different combinations with utomilumab, anti-OX40 antibody PF-04518600, and radiation therapy in treating patients with malignancies that have spread to…
- Conditions
- Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03217747
- Testing
- Avelumab, Ivuxolimab, Radiation Therapy
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.
- Trial name
- NCT04015700
- Testing
- Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
A Study of E7130 in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
- Trial name
- NCT03444701
- Testing
- E7130
- Where
- 9 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eisai Co., Ltd.
Solid Neoplasms
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone…
- Trial name
- iintune-1 (NCT04420884)
- Testing
- Dazostinag, Pembrolizumab, Platinum
- Where
- 62 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Takeda
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage…
- Conditions
- Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Trial name
- NCT00972478
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 190 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural…
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Trial name
- NCT01064648
- Testing
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis
- Where
- 230 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02158091
- Testing
- IPI-145, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Biphasic Mesothelioma, Epithelioid Mesothelioma
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma.
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
- Trial name
- NCT03228537
- Testing
- Atezolizumab, Cisplatin, Extrapleural Pneumonectomy
- Where
- 174 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with…
- Trial name
- J-MIND (NCT04661007)
- Testing
- tafasitamab, lenalidomide, parsaclisib
- Where
- 23 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Incyte Biosciences Japan GK
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
This phase Ib/II trial studies the side effects of IRX-2, cyclophosphamide, and pembrolizumab work in treating participants with gastric or gastroesophageal junction cancer that has come back or that has spread to other places in…
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03918499
- Testing
- Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Tumors
Phase 1 Study of E7090 in Subjects With Solid Tumor
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects…
- Trial name
- NCT02275910
- Testing
- E7090
- Where
- 18 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eisai Co., Ltd.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02993146
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Sars-CoV2, Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
*At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Trial name
- NCT04345601
- Testing
- Mesenchymal Stromal Cells, Supportive Care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.